Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Ven…

2024 ASH Annual Meeting Insights Hub

J. Brown

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

Current Guideline-Informed Treatment of CLL

Fred Hutchinson Cancer Center

C. Ujjani

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results Fr…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L C…

2024 ASH Annual Meeting Insights Hub

M. Davids

ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dos…

2024 ASH Annual Meeting Insights Hub

M. Shadman